Overview
This observational, multicentric prospective study aims to understand the prevalence and burden of antimicrobial resistance (AMR) in people with chronic lung diseases (CLD) across the globe, understanding also geographical variability and the risk factors for acquiring AMR.
The primary objective is to understand the prevalence and burden of AMR in CLD both at a local and gloval level.
Secondary objectives include: 1) understanding susceptibilities models of high priority pathogens in people with CLD; 2) understanding geographic variability in the prevalence of AMR in CLD; 3) analysing risk factors for AMR in CLD Participants will be recruited
Description
This is an observational prospective, non-pharmacological, multicentre, international, non-profit study. Data will be collected at all participating centres during two separate two-week periods every year over the course of five consecutive years. Patients with underlying chronic lung diseases in an inpatient or outpatient setting with at least one respiratory sample collected over the prior 12 months will be included. The diagnostic criteria will follow standard clinical procedures. The data will be pseudonymized before being entered into the electronic case report form (eCRF) prepared with RedCap. After signing the informed consent, clinical, demographic, and microbiological variables will be collected. To facilitate the collection of some demographic and clinical variables, a questionnaire will be administered at recruitment.
All procedures whose data will be collected for this protocol fall within normal clinical practice and are in accordance with the standard operating procedures in place at the centre. No procedures, diagnostic tests, or interventions outside the usual clinical practice will be performed for this protocol.
Eligibility
Inclusion Criteria:
- Patients of all ages with any chronic lung disease who, for clinical practice, underwent testingof at least one respiratory biological sample (sputum culture; bronchoaspirate; bronchoalveolar lavage; nasal swab; throat swab) within the 12 months prior to the visit.
- Patients attending an outpatient clinic or hospitalized during the study period
Exclusion Criteria:
- Patients who have not signed the informed consent form
- Absence of data in the patient record
